Evogene LTD Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ
Evogene Ltd. shareholders Kfir Silberman and Eli Zamir, along with their affiliated entities, have announced their intention to launch a special tender offer to acquire a significant stake in the company.
NASDAQ
Evogene Ltd. announces an amendment to its Schedule 13D filing, detailing Leon Recanati's acquisition of an additional 1,260,000 ordinary shares through at-the-market offerings.
NASDAQ
L.I.A. Pure Capital and Invest-Pro criticize Evogene's track record and urge shareholders to vote for their board nominees.
NASDAQ
L.I.A. Pure Capital Ltd. and associated entities have amended their Schedule 13D filing to report an increase in their beneficial ownership of Evogene Ltd. ordinary shares and ADSs.
NASDAQ
Leon Recanati, a board member of Evogene Ltd., has increased his beneficial ownership to 8.6% by acquiring an additional 460,000 ordinary shares.
NASDAQ
Leon Recanati, a board member and significant shareholder, has disclosed an increased stake in Evogene Ltd. and declared his intention to vote in favor of the current board's nominees in an upcoming contested director election.
NASDAQ
Shareholder group reiterates demand for special meeting and board refreshment, rejecting company's settlement proposals.
NASDAQ
L.I.A. Pure Capital Ltd. and affiliated entities have increased their beneficial ownership in Evogene Ltd. to 16.81% through open market purchases of American Depositary Shares.
NASDAQ
Major shareholders have formally demanded a special general meeting to replace most of Evogene's board of directors, citing financial underperformance and a need for strategic refreshment.